Filter results by
Search HelpKeyword(s)
Geography
Survey or statistical program
Results
All (6)
All (6) ((6 results))
- Table: 13-10-0867-01Geography: CanadaFrequency: OccasionalDescription: Long term symptoms were defined as having COVID-19 symptoms at least 3 months after a self-reported positive test or suspected SARS-CoV-2 infection. Results on the status of long-term symptoms only included respondents for whom a period of three months separated their self-reported date of infection and the date they completed the questionnaire.Release date: 2023-08-03
- Table: 13-10-0868-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription: This survey provides new evidence about those who indicated on their electronic questionnaire a positive test result with either a positive polymerase chain reaction (PCR) test or a rapid antigen test (RAT), as well as those who suspected that they had an infection. These results are based on the individual's self-reported first positive test result or first suspected infection and does not account for multiple infections.Release date: 2023-08-03
- Public use microdata: 13-25-0009Description: This public use microdata file (PUMF) provides researchers access to data on the distribution of SARS-CoV-2 lineages detected in the Canadian provinces between May and September 2022. Samples were collected as part of the Canadian COVID-19 Antibody and Health Survey (CCAHS), Cycle 2. The PUMF file consists of a subset of participants of the CCAHS who submitted a positive PCR saliva sample over the course of the collection of the survey. The PUMF contains select demographic information including sex at birth, age group, province and the week of collection. The file also contains SARS-CoV-2 whole genome sequences and its associated data.Release date: 2023-05-25
- Table: 13-10-0866-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription: Dried blood spot testing was used to detect antibodies against SARS-CoV-2, the virus that causes COVID-19. The proportion of Canadians who have antibodies from infection is referred to as the seroprevalence of SARS-CoV-2.Release date: 2023-03-27
- Public use microdata: 13-25-0007Description:
This public use microdata file (PUMF) contains data for a wide variety of variables collected from the Canadian COVID-19 Antibody and Health Survey (CCAHS). The CCAHS collected information on the presence of chronic conditions, self-reported COVID-19 status, testing history, risk for infection, health behaviours, vaccination status and intentions to get vaccinated. COVID-19 antibody seroprevalence laboratory data, and select demographic information are also available. Survey data were collected between November 2020 and April 2021, with the vast majority of collection occurring in January and February 2021.
Release date: 2022-11-16 - 6. SARS-CoV-2 antibody seroprevalence in Canadians, by age group and sex, November 2020 to April 2021Table: 13-10-0818-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription:
Seroprevalence of Canadians aged 1 and older with antibodies against SARS-CoV-2 (the virus that causes COVID-19), overall and by antibody type, by age group and sex.
Release date: 2021-07-06
Tables (4)
Tables (4) ((4 results))
- Table: 13-10-0867-01Geography: CanadaFrequency: OccasionalDescription: Long term symptoms were defined as having COVID-19 symptoms at least 3 months after a self-reported positive test or suspected SARS-CoV-2 infection. Results on the status of long-term symptoms only included respondents for whom a period of three months separated their self-reported date of infection and the date they completed the questionnaire.Release date: 2023-08-03
- Table: 13-10-0868-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription: This survey provides new evidence about those who indicated on their electronic questionnaire a positive test result with either a positive polymerase chain reaction (PCR) test or a rapid antigen test (RAT), as well as those who suspected that they had an infection. These results are based on the individual's self-reported first positive test result or first suspected infection and does not account for multiple infections.Release date: 2023-08-03
- Table: 13-10-0866-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription: Dried blood spot testing was used to detect antibodies against SARS-CoV-2, the virus that causes COVID-19. The proportion of Canadians who have antibodies from infection is referred to as the seroprevalence of SARS-CoV-2.Release date: 2023-03-27
- 4. SARS-CoV-2 antibody seroprevalence in Canadians, by age group and sex, November 2020 to April 2021Table: 13-10-0818-01Geography: Canada, Geographical region of Canada, Province or territoryFrequency: OccasionalDescription:
Seroprevalence of Canadians aged 1 and older with antibodies against SARS-CoV-2 (the virus that causes COVID-19), overall and by antibody type, by age group and sex.
Release date: 2021-07-06
Profiles of a community or region (0)
Profiles of a community or region (0) (0 results)
No content available at this time.
Thematic maps (0)
Thematic maps (0) (0 results)
No content available at this time.
Public use microdata (2)
Public use microdata (2) ((2 results))
- Public use microdata: 13-25-0009Description: This public use microdata file (PUMF) provides researchers access to data on the distribution of SARS-CoV-2 lineages detected in the Canadian provinces between May and September 2022. Samples were collected as part of the Canadian COVID-19 Antibody and Health Survey (CCAHS), Cycle 2. The PUMF file consists of a subset of participants of the CCAHS who submitted a positive PCR saliva sample over the course of the collection of the survey. The PUMF contains select demographic information including sex at birth, age group, province and the week of collection. The file also contains SARS-CoV-2 whole genome sequences and its associated data.Release date: 2023-05-25
- Public use microdata: 13-25-0007Description:
This public use microdata file (PUMF) contains data for a wide variety of variables collected from the Canadian COVID-19 Antibody and Health Survey (CCAHS). The CCAHS collected information on the presence of chronic conditions, self-reported COVID-19 status, testing history, risk for infection, health behaviours, vaccination status and intentions to get vaccinated. COVID-19 antibody seroprevalence laboratory data, and select demographic information are also available. Survey data were collected between November 2020 and April 2021, with the vast majority of collection occurring in January and February 2021.
Release date: 2022-11-16
Data Visualization (0)
Data Visualization (0) (0 results)
No content available at this time.
- Date modified: